You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 15, 2025

Patent: 9,441,278


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,441,278
Title:Genotyping method for use in cattle traceability and means thereof
Abstract: The invention discloses means and methods for genotyping an individual head of cattle. Individual\'s DNA is genotyped utilizing the herein defined PCR SNaP-shot protocol. The protocol comprises two PCR steps where the first step (PCR1) includes adding primers (SEQ ID No. 1-30) and/or primers extended at their 5\' end with a common 10 base motif (ACGTTGGATG) to the PCR1 reaction. The second step (PCR2) includes adding extension primers (SEQ ID No. 31-45), and/or primers adjacent to corresponding specific SNPs. Further steps include producing amplicons from a PCR1 mixture comprising template DNA and the first primer set to yield PCR1 products, using PCR1 products as templates to a set of extension primers to yield PCR2 products. Size and color separation is achieved by adding tails of different lengths to the PCR2 primers. PCR2 products are separated and the results compared with SNP profiles from the databank to obtain matching.
Inventor(s): Cahana; Aviv (Moshav Sitria, IL), Shirak; Andrey (Petach Tikva, IL), Karniol; Baruch (Bat Yam, IL), Skalsky; Yitzchak (Nitzan M.P. Evtach, IL), Weller; Joel Ira (Rehovot, IL), Ron; Micha (Nes Tziona, IL), Seroussi; Eyal (Sha\'arei Tikva, IL)
Assignee: BACTOCHEM LTD. (Nes Ziona, IL) STATE OF ISRAEL, MINISTRY OF AGRICULTURE AND RURAL DEVELOPMENT, A.R.O.--VOLCANI CENTER (Beit Dagan, IL)
Application Number:13/000,314
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 9,441,278

Introduction

United States Patent 9,441,278, hereafter referred to as the '278 patent, is a significant patent that has likely been subject to various analyses and challenges within the U.S. patent system. To provide a comprehensive and critical analysis, we will delve into the patent's claims, the broader patent landscape, and the relevant legal and procedural frameworks.

Understanding the Patent Claims

The '278 patent, like any other, consists of a set of claims that define the scope of the invention. These claims are crucial as they determine what is protected under the patent. Here are some key points to consider:

Claim Construction

The claims of the '278 patent would be interpreted using the principles outlined in the Alice/Mayo test, which determines whether the claims are directed to ineligible subject matter such as laws of nature, natural phenomena, or abstract ideas[2].

Novelty and Non-Obviousness

For a patent to be valid, its claims must meet the statutory requirements of novelty (35 U.S.C. § 102) and non-obviousness (35 U.S.C. § 103). The patent office and any subsequent challenges would scrutinize these aspects to ensure the invention is new and not obvious to a person of ordinary skill in the relevant field[4].

The Patent Landscape

The patent landscape surrounding the '278 patent includes various factors such as geographical distribution of patent activity, patent litigation trends, and the role of administrative challenges.

Geographical Distribution of Patent Activity

The geographical distribution of patent activity can provide insights into the regions where inventors and patent owners are most active. Data from the USPTO's PatentsView database shows that patent intensity varies significantly across different counties and regions in the United States. This data can help in understanding the regional impact of patents like the '278 patent[1].

Patent Litigation Trends

Patent litigation is a critical aspect of the patent landscape. The USPTO's Patent Litigation Docket Report Data provides comprehensive information on patent litigation cases, including the types of cases, litigating parties, and outcomes. This data can help in assessing the likelihood of litigation involving the '278 patent and the potential costs and outcomes associated with such litigation[3].

Administrative Challenges: PTAB and Inter Partes Review

The Leahy-Smith America Invents Act (AIA) introduced significant changes to the U.S. patent system, including the creation of the Patent Trial and Appeal Board (PTAB) and procedures like inter partes review (IPR) and post-grant review (PGR).

PTAB and IPR/PGR

PTAB provides a faster and less expensive alternative to federal court litigation for challenging the validity of patents. IPR and PGR allow parties to petition PTAB to review the validity of an already-issued patent, which can result in the cancellation of patent claims if PTAB determines they should not have been issued. This mechanism is particularly relevant for patents like the '278 patent, as it can be challenged through these administrative procedures[2].

Impact on Patent Quality and Litigation

The creation of PTAB and the introduction of IPR and PGR were aimed at improving patent quality and reducing unwarranted litigation costs. However, critics argue that these mechanisms have made it too easy to challenge patents, creating uncertainty in patent rights and potentially stifling innovation[2].

Patent Quality and Examination

The quality of patents is a recurring theme in discussions around patent policy. Here are some points related to patent quality and the examination process:

USPTO's Enhanced Patent Quality Initiative

The USPTO has implemented various initiatives to improve patent quality, including the Enhanced Patent Quality Initiative. This initiative involves setting correctness measures and quantifiable compliance targets to ensure that patents meet statutory requirements[4].

Definition of Patent Quality

There is an ongoing debate about the definition of patent quality. Stakeholders generally agree that a quality patent should meet the statutory requirements for novelty, clarity, and non-obviousness and should be upheld if challenged in a lawsuit or other proceeding. However, the USPTO has yet to articulate a consistent definition of patent quality in its agency documents and guidance[4].

Use of AI Tools in Patent Applications

The increasing use of AI tools in patent applications raises new challenges and considerations.

Disclosure Requirements

If AI tools are used in the development of a patent application, this must be disclosed to the USPTO. This includes any material information that could affect the patentability of the invention, such as contributions made by AI systems that may not be attributed to human inventors[5].

Inventorship and Contribution

The use of AI tools also raises questions about inventorship. Practitioners must assess whether the contributions made by natural persons rise to the level of inventorship, ensuring that AI contributions do not introduce inaccurate statements or omit material information[5].

Key Takeaways

  • Claims Analysis: The claims of the '278 patent must be carefully constructed and interpreted to ensure they meet statutory requirements.
  • Patent Landscape: Understanding the geographical distribution of patent activity and litigation trends is crucial for assessing the patent's impact and potential challenges.
  • Administrative Challenges: PTAB and IPR/PGR provide mechanisms for challenging patent validity, which can significantly impact the '278 patent.
  • Patent Quality: Ensuring patent quality through initiatives like the Enhanced Patent Quality Initiative is vital for maintaining the integrity of the patent system.
  • AI Tools: The use of AI tools in patent applications requires careful disclosure and assessment to ensure compliance with patent laws.

FAQs

Q: What is the significance of the Leahy-Smith America Invents Act (AIA) in the context of patent challenges? A: The AIA introduced the Patent Trial and Appeal Board (PTAB) and procedures like inter partes review (IPR) and post-grant review (PGR), providing faster and less expensive alternatives to federal court litigation for challenging patent validity.

Q: How does the USPTO define patent quality? A: The USPTO has not articulated a consistent definition of patent quality in its agency documents and guidance, although stakeholders generally agree that a quality patent should meet statutory requirements and be upheld if challenged.

Q: What are the implications of using AI tools in patent applications? A: The use of AI tools requires disclosure to the USPTO, and practitioners must ensure that AI contributions do not introduce inaccurate statements or omit material information, and that human inventors' contributions meet the criteria for inventorship.

Q: How does the geographical distribution of patent activity affect the '278 patent? A: The geographical distribution can provide insights into the regions where inventors and patent owners are most active, which can influence the patent's impact and potential challenges.

Q: What is the role of PTAB in maintaining patent quality? A: PTAB plays a crucial role in maintaining patent quality by providing a mechanism to challenge the validity of patents, thereby helping to weed out poor-quality patents and reduce unwarranted litigation costs.

Sources

  1. National Science Foundation, "Invention, Knowledge Transfer, and Innovation," Science and Engineering Indicators 2022: Technical Documentation, March 8, 2022.
  2. Congressional Research Service, "The Patent Trial and Appeal Board and Inter Partes Review," R48016, Updated May 28, 2024.
  3. U.S. Patent and Trademark Office, "Working papers and book chapters," USPTO Economic Research, March 2024.
  4. Government Accountability Office, "Intellectual Property: Patent Office Should Define Quality, Reassess Processes," GAO-16-490, June 30, 2016.
  5. Buchanan Ingersoll & Rooney PC, "U.S. Patent Office Issues Additional Guidance on Use of AI Tools," April 15, 2024.

More… ↓

⤷  Try for Free

Details for Patent 9,441,278

ApplicantTradenameBiologic IngredientDosage FormBLAApproval DatePatent No.Expiredate
Insmed Incorporated IPLEX mecasermin rinfabate Injection 021884 December 12, 2005 9,441,278 2028-06-19
>Applicant>Tradename>Biologic Ingredient>Dosage Form>BLA>Approval Date>Patent No.>Expiredate
Showing 1 to 1 of 1 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.